Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Axogen Inc(AXGN)
Top performer •
Today’s top pick 
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for AXGN
11/13/2026: AXGN (4-star) is a STRONG-BUY. BUY for 9 days. Simulated Profits (12.99%). Updated daily EoD!
Axogen Inc is a specialized medical technology company focused on surgical solutions for peripheral nerve repair. The company has a leading position in its niche, utilizing products like the Avance Nerve Graft to displace traditional autograft techniques through a strong evidence-based commercial model. Its primary growth opportunity lies in increasing market penetration among surgeons and expanding into new clinical indications. Key risks include the company's reliance on a specialized surgical market, competition from larger medtech players, and the ongoing need to demonstrate consistent profitability. Axogen may suit growth-oriented investors who can tolerate the volatility typically associated with scaling medtech companies and should monitor quarterly operating margins.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Axogen fits growth profiles focused on companies expanding their market share in the niche field of peripheral nerve repair. |
| Momentum investor | Mixed fit | Momentum suitability is conditional on positive technical trends and sustained revenue growth signals. |
| Value investor | Weak fit | The company's focus on growth and intermittent profitability makes it less suitable for traditional value-based investment strategies. |
| Dividend investor | Weak fit | Axogen does not pay dividends, making it unsuitable for income-focused investors. |
| Low-risk investor | Weak fit | The company's status as a growth-stage medical device firm involves higher volatility and execution risks. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Small-to-mid-cap medical device stocks often experience significant price swings based on clinical data or market conditions. |
| Valuation risk | Medium / high | Growth expectations are heavily baked into the share price, leaving little room for error in quarterly results. |
| Competition risk (medtech giants) | Medium / high | Larger competitors with diversified portfolios could leverage bundled sales to challenge Axogen's niche position. |
| Business quality | Medium | While the product portfolio is specialized and clinically supported, the company has yet to demonstrate long-term, consistent profitability. |
| Dividend income | Low / none | Investors should expect no income, as all capital is prioritized for business reinvestment. |
| Execution risk | Medium | Successful long-term growth depends on the continued effective training of surgeons and management of commercial operations. |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.31B USD | Price to earnings Ratio - | 1Y Target Price 59.27 |
Price to earnings Ratio - | 1Y Target Price 59.27 | ||
Volume (30-day avg) 1.9M shares | Beta 1.15 | 52 Weeks Range 23.00 - 59.72 | Updated Date 11/13/2026 |
52 Weeks Range 23.00 - 59.72 | Updated Date 11/13/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.63 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Medical Devices
- BUY participation
- 62.5%
- Active BUY / eligible
- 5 / 8
- 30-Day BUY Count Change
- +3
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 228.38% | Avg. Invested days 39 | Today’s Advisory Strong Buy |
Upturn Advisory Rating  | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 11/13/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Nerve Repair Products | Revenue from the sale of Avance Nerve Graft, Axoguard Nerve Connector, and Axoguard Nerve Protector. | The company makes money by selling proprietary, specialized medical products that surgeons use to repair nerves. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-10-28 | When Before Market | Estimate -0.03 | Actual 0.04 |
Profitability
Profit Margin -11.96% | Operating Margin (TTM) -5.17% |
Management Effectiveness
Return on Assets (TTM) -2.25% | Return on Equity (TTM) -10.35% |
Valuation
Trailing PE - | Forward PE 128.21 | Enterprise Value 2.98B | Price to Sales(TTM) 12.4 |
Enterprise Value 2.98B | Price to Sales(TTM) 12.4 | ||
Enterprise Value to Revenue 11.89 | Enterprise Value to EBITDA 79.43 | Shares Outstanding 59.73M | Shares Floating 54.61M |
Shares Outstanding 59.73M | Shares Floating 54.61M | ||
Percent Insiders 1.94 | Percent Institutions 99.44 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.